医学信息
醫學信息
의학신식
MEDICAL INFORMATION
2014年
22期
241-241,242
,共2页
艾迪注射液%靶向药物%非小细胞肺癌%吉非替尼
艾迪註射液%靶嚮藥物%非小細胞肺癌%吉非替尼
애적주사액%파향약물%비소세포폐암%길비체니
Aide injection%Targeted drugs%Non-smal celllung cancer%Gefitinib
目的：观察艾迪注射液联合靶向药物在治疗非小细胞肺癌中的应用及疗效。方法选取了2012年2月~2013年2月我院收治的非小细胞肺癌患者共46例，均为拒绝放化疗的患者，按照随机原则将其分为对照组和观察组各23例，对照组采用艾迪注射液方式进行治疗，观察组在对照组治疗基础上联合靶向药物进行治疗，治疗后对两组患者近期疗效进行对比，并在出院后3~12个月随访患者生存状况。结果调查结果显示，观察组治疗总有效率为78.3%，随访12个月中死亡3例，生存率为86.9%，无明显毒副作用；对照组中近期治疗总有效率为69.6%，随访中死亡4例，生存率为82.6%，组间对比差异有统计学意义(P<0.05)。结论艾迪注射液联合靶向药物在治疗非小细胞肺癌具有较好疗效，值得在临床上进行推广和应用。
目的：觀察艾迪註射液聯閤靶嚮藥物在治療非小細胞肺癌中的應用及療效。方法選取瞭2012年2月~2013年2月我院收治的非小細胞肺癌患者共46例，均為拒絕放化療的患者，按照隨機原則將其分為對照組和觀察組各23例，對照組採用艾迪註射液方式進行治療，觀察組在對照組治療基礎上聯閤靶嚮藥物進行治療，治療後對兩組患者近期療效進行對比，併在齣院後3~12箇月隨訪患者生存狀況。結果調查結果顯示，觀察組治療總有效率為78.3%，隨訪12箇月中死亡3例，生存率為86.9%，無明顯毒副作用；對照組中近期治療總有效率為69.6%，隨訪中死亡4例，生存率為82.6%，組間對比差異有統計學意義(P<0.05)。結論艾迪註射液聯閤靶嚮藥物在治療非小細胞肺癌具有較好療效，值得在臨床上進行推廣和應用。
목적：관찰애적주사액연합파향약물재치료비소세포폐암중적응용급료효。방법선취료2012년2월~2013년2월아원수치적비소세포폐암환자공46례，균위거절방화료적환자，안조수궤원칙장기분위대조조화관찰조각23례，대조조채용애적주사액방식진행치료，관찰조재대조조치료기출상연합파향약물진행치료，치료후대량조환자근기료효진행대비，병재출원후3~12개월수방환자생존상황。결과조사결과현시，관찰조치료총유효솔위78.3%，수방12개월중사망3례，생존솔위86.9%，무명현독부작용；대조조중근기치료총유효솔위69.6%，수방중사망4례，생존솔위82.6%，조간대비차이유통계학의의(P<0.05)。결론애적주사액연합파향약물재치료비소세포폐암구유교호료효，치득재림상상진행추엄화응용。
Objective To observe the Aide injection combined with targeted agents in the application and ef icacy of the treatment of non-smal celllung cancer. Methods The February 2012 to February 2013 I lung cancer patients admit ed to the hospital a total of 46 cases of non-smal cell,patients were refused chemotherapy,according randomly divided into a control group and observation group,23 cases in the control group using Aide injection mode treatment,combined joint observation group targeted drugs in the treatment of the control group on the basis of treatment,after the recent two groups of patients were compared the ef icacy and survival in patients fol owed up for 3~12 months after discharge.Results The survey showed that the total ef ective rate of observation group was 78.3%,fol owed up for 12 months,3 patients died ,the survival rate was 86.9%,no significant side ef ects;recent treatment control group total ef ective rate of 69.6%,fol ow-up 4 deaths,survival rate was 82.6%,compared to the dif erences between the two groups was statistical y significant( <0.05).Conclusion Audi injection combined with targeted agents in the treatment of non-smal celllung cancer have bet er ef icacy,patient prognosis is good,worthy of promotion and application in clinical practice.
